Oligodendroglioma Pipeline Review, H2 2018 - ResearchAndMarkets.com
The "Oligodendroglioma - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Oligodendroglioma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 9, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Oligodendroglioma - Overview
- Oligodendroglioma - Therapeutics Development
- Oligodendroglioma - Therapeutics Assessment
- Oligodendroglioma - Companies Involved in Therapeutics Development
- Oligodendroglioma - Drug Profiles
- Oligodendroglioma - Dormant Projects
- Oligodendroglioma - Discontinued Products
- AbbVie Inc
- AlfaSigma SpA
- AngioChem Inc
- Astellas Pharma Inc
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Eli Lilly and Co
- GtreeBNT Co Ltd
- Immatics Biotechnologies GmbH
- Ipsen SA
- Northwest Biotherapeutics Inc
- Novartis AG
- Pfizer Inc
- Taiho Pharmaceutical Co Ltd
- TheraBiologics Inc
- Tocagen Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vtsn55/oligodendroglioma?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181012005104/en/